Hemalatha Sundaramoorthi

Hemalatha Sundaramoorthi

Auto-generated profile, based on publicly available information

Hemalatha Sundaramoorthi

Division of Oncology, Washington University School of Medicine, St Louis, Missouri, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2019 in JCI Insight
Verified
Journal Article
Open access
PDF file
JXJingyu Xiang
Jingyu Xiang
DRDaniel Rauch
Daniel Rauch
DHDevra Huey
Devra Huey
APAmanda Panfil
Amanda Panfil
XCXiaogang Cheng
Xiaogang Cheng
KWKatherine N. Weilbaecher
Katherine N. Weilbaecher
Osteolytic bone lesions and hypercalcemia are common, serious complications in adult T cell leukemia/lymphoma (ATL), an aggressive T cell malignancy associated with human T cell leukemia virus type 1 (HTLV-1) infection. The HTLV-1 viral oncogene HBZ has been implicated in ATL tumorigenesis and bone loss. In this study, we evaluated the role of HBZ on ATL-associated bone destruction using HTLV-1 infection and disease progression mouse models. Humanized mice infected with HTLV-1 developed lymphoproliferative disease and continuous, progressive osteolytic bone lesions. HTLV-1 lacking HBZ displayed only modest delays to lymphoproliferative disease but significantly decreased disease-associated bone loss compared with HTLV-1–infected mice. Gene expression array of acute ATL patient samples demonstrated increased expression of RANKL , a critical regulator of osteoclasts. We found that HBZ regulated RANKL in a c-Fos–dependent manner. Treatment of HTLV-1–infected humanized mice with denosumab, a monoclonal antibody against human RANKL, alleviated bone loss. Using patient-derived xenografts from primary human ATL cells to induce lymphoproliferative disease, we also observed profound tumor-induced bone destruction and increased c-Fos and RANKL gene expression. Together, these data show the critical role of HBZ in driving ATL-associated bone loss through RANKL and identify denosumab as a potential treatment to prevent bone complications in ATL patients.

1 January 2015 in Blood Cells, Molecules, and Diseases
Verified
Journal Article
Closed access
SKSeongcheol Kim
Seongcheol Kim
HSHemalatha Sundaramoorthi
Hemalatha Sundaramoorthi
PJPudur Jagadeeswaran
Pudur Jagadeeswaran

8 November 2022 in Case Reports in Oncology
Verified
Journal Article
Open access
PDF file
SPSneha Poondru
Sneha Poondru
AJAncy Joseph
Ancy Joseph
JHJohn C. Harding
John C. Harding
HSHemalatha Sundaramoorthi
Hemalatha Sundaramoorthi
NMNeha Mehta-Shah
Neha Mehta-Shah
LRLee E. E. Ratner
Lee E. E. Ratner
Human T-cell leukemia virus type 1 (HTLV-1) is an oncogenic retrovirus. Of the approximate ten to twenty million people currently infected worldwide, 4–9% of infected individuals develop adult T-cell leukemia/lymphoma (ATLL) or HTLV-associated myelopathy/tropical spastic paresis (HAM/TSP) in their lifetime. The current report is based on a patient who presented concurrently with CD30+ lymphoma subtype ATLL and HAM/TSP. The patient’s ATLL responded to brentuximab-vedotin-based chemotherapy; however, HAM/TSP did not improve. The patient’s peripheral blood mononuclear cells were cultured and injected into immunodeficient mice, and the mice developed massive organ involvement and chronic lymphocytic leukemia-subtype ATLL. This case study is novel in the findings of concurrent development of ATLL and HAM/TSP, the response to brentuximab-vedotin chemotherapy, and the use HTLV-1 helix basic zipper protein-targeted probe for RNAscope for diagnosis.